

World Journal of *Gastroenterology*

World J Gastroenterol 2022 December 28; 28(48): 6791-6961



REVIEW

- 6791 COVID-19 vaccination and liver disease
Ozaka S, Kobayashi T, Mizukami K, Murakami K
- 6811 Mechanism and potential treatments for gastrointestinal dysfunction in patients with COVID-19
Yao Y, Liu ZJ, Zhang YK, Sun HJ
- 6827 Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options
Zhang CY, Liu S, Yang M
- 6846 Bile acids and microbes in metabolic disease
Sah DK, Arjunan A, Park SY, Jung YD

MINIREVIEWS

- 6867 Recent advances in the management of autoimmune pancreatitis in the era of artificial intelligence
Mack S, Flattet Y, Bichard P, Frossard JL
- 6875 Molecular mechanisms implicated in SARS-CoV-2 liver tropism
Quarleri J, Delpino MV
- 6888 Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease
Xu YH, Zhu WM, Guo Z
- 6900 Confusion and prospects for carcinogenesis of gastric adenoma and dysplasia: What is the correct answer currently?
Kinami S, Yamada S, Takamura H
- 6909 Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease
Bukke VN, Moola A, Serviddio G, Vendemiale G, Bellanti F
- 6922 Current and future perspectives on acute-on-chronic liver failure: Challenges of transplantation, machine perfusion, and beyond
Della Guardia B, Boteon APCS, Matielo CEL, Felga G, Boteon YL

ORIGINAL ARTICLE**Basic Study**

- 6935 Bladder-colon chronic cross-sensitization involves neuro-glial pathways in male mice
Atmani K, Wuestenberghs F, Baron M, Bouleté I, Guérin C, Bahlouli W, Vaudry D, do Rego JC, Cornu JN, Leroi AM, Coëffier M, Meleine M, Gourcerol G

Retrospective Study

- 6950** Clinical features and long-term outcomes of patients with colonic oligopolyposis of unknown etiology
Feldman D, Rodgers-Fouche L, Hicks S, Chung DC

ABOUT COVER

Editorial Board of *World Journal of Gastroenterology*, Xi-Dai Long, MD, PhD, Professor, Department of Pathology, the Affiliated Hospital of Youjiang Medical University for Nationalities, BOSE 533000, Guangxi, China.
sjtulongxd@263.net

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (*WJG*, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. *WJG* mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The *WJG* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for *WJG* as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The *WJG*'s CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Yu-Xi Chen*; Production Department Director: *Xu Guo*; Editorial Office Director: *Jia-Ru Fan*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

December 28, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Basic Study

Bladder-colon chronic cross-sensitization involves neuro-glia pathways in male mice

Karim Atmani, Fabien Wuestenberg, Maximilien Baron, Illona Bouleté, Charlene Guérin, Wafa Bahlouli, David Vaudry, Jean Claude do Rego, Jean-Nicolas Cornu, Anne-Marie Leroi, Moïse Coëffier, Mathieu Meleine, Guillaume Gourcerol

Specialty type: Neurosciences

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): D, D
Grade E (Poor): 0

P-Reviewer: Han J, China; Lu Q, China

Received: May 18, 2022

Peer-review started: May 18, 2022

First decision: August 1, 2022

Revised: October 2, 2022

Accepted: October 26, 2022

Article in press: October 26, 2022

Published online: December 28, 2022



Karim Atmani, Fabien Wuestenberg, Maximilien Baron, Illona Bouleté, Charlene Guérin, Wafa Bahlouli, David Vaudry, Jean-Nicolas Cornu, Anne-Marie Leroi, Moïse Coëffier, Mathieu Meleine, Guillaume Gourcerol, Nutrition, Gut and Brain Unit (Inserm U1073), Institute for Research and Innovation in Biomedicine, Université de Rouen Normandie, Rouen 76000, France

Fabien Wuestenberg, Department of Gastroenterology and Hepatology, Université Catholique de Louvain, CHU UCL Namur, Yvoir 5530, Belgium

Fabien Wuestenberg, Anne-Marie Leroi, Guillaume Gourcerol, Department of Physiology, CHU Rouen, Université de Rouen Normandie, Rouen 76031, France

Maximilien Baron, Jean-Nicolas Cornu, Department of Urology, CHU Rouen, Université de Rouen Normandie, Rouen 76000, France

David Vaudry, Inserm, UMR 1245, Team Epigenetics and Pathophysiology of Neurodevelopmental Disorders, Université de Rouen Normandie, Rouen 76000, France

Jean Claude do Rego, Behavioural Analysis Platform (SCAC), HeRacLeS Inserm US51-CNRS UAR2026, Institute for Research and Innovation in Biomedicine, Université de Rouen Normandie, Rouen 76000, France

Moïse Coëffier, Department of Nutrition, CHU Rouen, Université de Rouen Normandie, Rouen 76000, France

Mathieu Meleine, Inserm U1107, NeuroDol, Clermont Auvergne University, Clermont-Ferrand 63000, France

Corresponding author: Guillaume Gourcerol, MD, PhD, Chief Doctor, Professor, Department of Physiology, CHU Rouen, Université de Rouen Normandie, 1 Rue de Germont, Rouen 76031, France. guillaume.gourcerol@chu-rouen.fr

Abstract**BACKGROUND**

Irritable bowel syndrome and bladder pain syndrome often overlap and are both characterized by visceral hypersensitivity. Since pelvic organs share common sensory pathways, it is likely that those syndromes involve a cross-sensitization of

the bladder and the colon. The precise pathophysiology remains poorly understood.

AIM

To develop a model of chronic bladder-colon cross-sensitization and to investigate the mechanisms involved.

METHODS

Chronic cross-organ visceral sensitization was obtained in C57BL/6 mice using ultrasound-guided intravesical injections of acetic acid under brief isoflurane anesthesia. Colorectal sensitivity was assessed in conscious mice by measuring intracolonic pressure during isobaric colorectal distensions. Myeloperoxidase, used as a marker of colorectal inflammation, was measured in the colon, and colorectal permeability was measured using chambers. c-Fos protein expression, used as a marker of neuronal activation, was assessed in the spinal cord (L6-S1 level) using immunohistochemistry. Green fluorescent protein on the fractalkine receptor-positive mice were used to identify and count microglia cells in the L6-S1 dorsal horn of the spinal cord. The expression of NK1 receptors and MAPK-p38 were quantified in the spinal cord using western blot.

RESULTS

Visceral hypersensitivity to colorectal distension was observed after the intravesical injection of acetic acid *vs* saline ($P < 0.0001$). This effect started 1 h post-injection and lasted up to 7 d post-injection. No increased permeability or inflammation was shown in the bladder or colon 7 d post-injection. Visceral hypersensitivity was associated with the increased expression of c-Fos protein in the spinal cord ($P < 0.0001$). In green fluorescent protein on the fractalkine receptor-positive mice, intravesical acetic acid injection resulted in an increased number of microglia cells in the L6-S1 dorsal horn of the spinal cord ($P < 0.0001$). NK1 receptor and MAPK-p38 levels were increased in the spinal cord up to 7 d after injection ($P = 0.007$ and 0.023 respectively). Colorectal sensitization was prevented by intrathecal or intracerebroventricular injections of minocycline, a microglia inhibitor, by intracerebroventricular injection of CP-99994 dihydrochloride, a NK1 antagonist, and by intracerebroventricular injection of SB203580, a MAPK-p38 inhibitor.

CONCLUSION

We describe a new model of cross-organ visceral sensitization between the bladder and the colon in mice. Intravesical injections of acetic acid induced a long-lasting colorectal hypersensitivity to distension, mediated by neuroglial interactions, MAPK-p38 phosphorylation and the NK1 receptor.

Key Words: Cross-organ sensitization; MAPK-p38; Microglia; NK1 receptor; Pain; Visceral hypersensitivity

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: A model of chronic cross-organ visceral sensitization in mice was developed using ultrasound-guided intravesical injections of acetic acid. Visceral hypersensitivity to colorectal distension was observed as early as 1 h post-injection and lasted up to 7 d. Visceral hypersensitivity was associated with an increased expression of c-Fos protein in the spinal cord. The NK1 receptor and MAPK-p38 levels were upregulated in the spinal cord 7 d post-injection. Colorectal sensitization was prevented by intrathecal or intracerebroventricular injections of minocycline, a microglia inhibitor, by intracerebroventricular injection of CP-99994, a NK1 antagonist, and by intracerebroventricular injection of SB203580, a MAPK-p38 inhibitor.

Citation: Atmani K, Wuestenberghs F, Baron M, Bouleté I, Guérin C, Bahlouli W, Vaudry D, do Rego JC, Cornu JN, Leroi AM, Coëffier M, Meleine M, Gourcerol G. Bladder-colon chronic cross-sensitization involves neuroglial pathways in male mice. *World J Gastroenterol* 2022; 28(48): 6935-6949

URL: <https://www.wjgnet.com/1007-9327/full/v28/i48/6935.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v28.i48.6935>

INTRODUCTION

Irritable bowel syndrome (IBS) and bladder pain syndrome (BPS) are two functional disorders that affect the gastrointestinal tract and the urinary tract, respectively[1,2]. Their prevalence in the general

population is 4.6% [3] and 4.2% [4], respectively, and recent studies have shown a strong overlap between both syndromes [1,2]. Indeed, BPS is found in 40%-60% of IBS patients [5], and IBS is observed in 25.4%-38.6% of BPS patients [1,2]. Both syndromes are characterized by visceral mechanical hypersensitivity at the urinary tract level for BPS and at the intestinal level for IBS [6,7]. The involvement of several mechanisms has been suggested in the onset and/or the maintenance of visceral hyperalgesia, including urothelial and/or intestinal epithelial permeability, mucosal immune activation and altered brain-gut interaction [8].

Despite increasing knowledge of the pathophysiology of IBS and BPS, limited mechanistic data is available in the context of BPS-IBS overlap. Based on the fact that pelvic organs share common sensory pathways, a few studies have offered evidence that cross-sensitization between the bladder and the colon may explain sensitization of both organs [9]. This may involve primary extrinsic afferents or central sensitization, both at the spinal and supraspinal levels [10]. All these studies involved acute sensitization models, often in anesthetized animals [11]; therefore, there is not yet any data regarding the chronicization of pelvic organ cross-sensitization.

The role of spinal glia has recently been highlighted in the sensitization of the bladder or colon [12] and even in cross-organ sensitization between both organs [13]. The role of spinal glia, however, has never been demonstrated in the maintenance of such sensitization using models of bladder-colon cross-sensitization induced chronic visceral hyperalgesia. The aims of our study were therefore to develop a model of chronic cross-organ sensitization between the bladder and the colon and to investigate the mechanisms involved in the development and persistence of this cross-sensitization.

MATERIALS AND METHODS

Ethics

The experiments were carried out in accordance with the ethical guidelines of the International Association for the Study of Pain [14] and in accordance with the guidelines of the French Ministry of Agriculture and Fisheries (Decree No. 874848). Our protocol was approved by the local Ethics Committee for Animal Experiments (CENOMEXA No: N/02-01-13/02/01-16).

Animals

Adult male wild type C57Bl/6 mice (Janvier Laboratories, Le Genest-Saint-Isle, France) and transgenic mice expressing the green fluorescent protein on the fractalkine receptor of microglial cells (Inserm Laboratory U1239, Dr. David Vaudry Team, Mont Saint Aignan, France [15]) were 8 wk old on the day of the experiment (weight range: 22-26 g). The animals were randomized by their weight in several cages, with five mice per cage, housed in a 12 h light/dark cycle in an animal housing facility free of specific pathogenic organisms and maintained at room temperature (22 ± 2 °C). The animals received a standard diet (RM1 diet; SDS, Witham, Essex, United Kingdom). Drinking water and food were available *ad libitum*. Each manipulation or experiment took place after at least 1 wk of acclimatization to the housing conditions. All animals were euthanized by cervical dislocation after anesthesia with ketamine (100 mg/kg, Imalgene 1000; Merial, Lyon, France) and xylazine (10 mg/kg, Rompun® 2%; Bayer, Berlin, Germany) administered intraperitoneally before tissue collection.

Study design

The animal protocol was designed to minimize pain or discomfort to the animals. Eight series of mice were used in this work. Each set was comprised of different groups of mice, and each group was formed of 5-8 mice. The first series was used to develop the cross-organ sensitization model. Once the model was validated, a second series was used to analyze inflammatory parameters in the colon and the bladder and to assess colonic and bladder permeabilities. We then focused on the central nervous system, especially at lamina I and II of the dorsal horn at the L6-S1 segment, where pelvic extrinsic primary afferent neurons form synapses with spinal neurons. Our third series assessed the neuronal activity in this model using c-Fos expression, and inflammatory parameters were measured in the spinal cord of a fourth series. The model was then transposed on transgenic mice to assess changes in microglia cells. Finally, three different inhibitors/antagonists were used in the sixth, seventh and eighth series to gain a better understanding of which pathway could be involved in the cross-sensitization process.

Acetic acid sensitization

An injection of acetic acid (0.75%, 200 μ L) or saline (NaCl 0.9%, 200 μ L; Baxter, Deerfield, IL, United States) was made into the urinary bladder using ultrasound monitoring in mice under brief anesthesia (isoflurane: 3% in 1.5 L/min of air, Iso-Vet®; Piramal Critical Care, Voorschoten, The Netherlands).

Colorectal distension and visceral sensitivity measurement

We measured visceral pain to colorectal distension (CRD) using a non-invasive method, as previously

reported in mice[16]. Changes in intracolonic pressure, reflecting visceromotor responses induced by CRD (nociceptive stimulus), were used as a surrogate marker of colorectal sensitivity[16].

An infinitely compliant distension balloon (diameter 0.7 cm) was made using a polyethylene bag attached to a PE-50 catheter (Intramedics, France) drilled in its end and taped 2 cm below the pressure sensor of a miniaturized pressure transducer catheter (SPR-524 Mikro-Tip catheter; Millar Instruments, Houston, TX, United States). Polypropylene 4-0 Ligatures (Prolène®; Ethicon Inc., Somerville, NJ, United States) were covered with parafilm to prevent any air leak.

On the experimental day, mice were briefly anesthetized with isoflurane (3% in air), and the lubricated “balloon-pressure sensor” was introduced into the colorectum, so that the balloon was inserted 2 cm upstream of the anal margin into the colon. Each mouse was placed in an adjustable mouse restrainer (30 mm diameter × 90 mm length, LE5016; *In Vivo* Research Instruments, Perkin Elmer, Waltham, MA, United States) and left to rest for 30 min before the CRD procedure. The balloon was then secured to the tail with tape and connected to an electronic barostat (Distender Series II; G & J Electronics Inc., Toronto, ON, Canada) to perform isobaric CRD. Our distension protocol consisted of a set of graded phasic distensions of 15, 30, 45 and 60 mmHg (two times each, 20 s duration, 4 min inter-stimulus interval) (Protocol Plus Deluxe; G & J Electronics, Toronto, ON, Canada). Voltage output was converted digitally using CED digital-analogic converter (Micro 1401; Cambridge Electronic Design, Cambridge, United Kingdom) and Spike 2 software (CED, Ltd., Cambridge, United Kingdom). The pressure sensor allowed the assessment of visceral pain *via* a custom-made script that allowed signals to be specifically extracted from abdominal muscle contractions (excluding those from colonic contractions).

Colonic sensitivity was measured in awake mice at 60 min, 3 d and 7 d following acetic acid urinary bladder injections.

Measurement of bladder and colonic paracellular permeabilities

After euthanasia, bladder and distal colon samples were removed on day 7. Samples were cut along the mesenteric border. Bladder and colonic permeabilities were assessed by measuring fluorescein isothiocyanate (FITC)-dextran (4 kDa) fluxes in Ussing chambers with an exchange surface of 0.07 cm² (Harvard Apparatus, Holliston, MA, United States) as previously described[17]. FITC-dextran (5 mg/mL) was loaded on the mucosal side. After 3 h at 37 °C, the medium from the contralateral side (serosa) was removed and stored at -80 °C. The fluorescence level of FITC-dextran (excitation at 485 nm, emission at 535 nm) was measured in a 96-well black plate using spectrometer Chameleon V (Hidex Co, Turku, Finland). The results were converted to concentrations of FITC-dextran (mg/mL) for analysis.

Myeloperoxidase measurement

After euthanasia, bladder and distal colon samples were removed on day 7. Colonic and vesical tissues (around 50 mg) were washed in phosphate-buffered saline and then homogenized (50 mg/mL) in 0.5% hexadecyltrimethylammonium bromide (Sigma-Aldrich, Steinheim, Germany) with 50 mmol/L of phosphate-buffered saline (pH 6.0). They were frozen at -80 °C and thawed at 37 °C three times, then sonicated (Vibra Cell ultrasonic processor 75115; Bioblock Scientific, Illkirch, France) and finally centrifuged (14000 rpm at 4 °C for 15 min). Myeloperoxidase (MPO) was assayed in the supernatant by adding 1 mg/mL of dianisidine dihydrochloride (Sigma-Aldrich) and 5 × 10⁻⁵% of hydrogen peroxide (Sigma-Aldrich). The change in optical density was measured at 450 nm. One unit of MPO activity was defined as the amount that degraded 1.0 μmol of hydrogen peroxide per minute at 25 °C, and human neutrophil MPO (Sigma-Aldrich) was used as standard, as previously described[18,19].

c-Fos immunofluorescence

Seven days after the intrabladder injection of acetic acid 0.75%, c-Fos immunohistochemistry was performed after 120 min of CRD at 45 mmHg (20 s of distension every 4 min for 120 min). Under ketamine (100 mg/kg i.p.)/xylazine (10 mg/kg) anesthesia and upon thoracotomy, mice were perfused through a cardiac-aorta cannula with saline followed by 150 mL/mouse of ice-cold 4% paraformaldehyde and 14% saturated picric acid in a 0.1 M phosphate buffer solution (pH 7.2). After decapitation, the lumbo-sacral spinal cord (L6-S1) was post-fixed in the same fixative solution overnight at 4 °C, cryoprotected by immersion in 10% sucrose overnight and transferred to 30% sucrose overnight. The spinal cords were then embedded in Tissue-Tek® optimal cutting temperature compound (Sakura Finetek United States, Inc., Torrance, CA, United States), snap-frozen and cut with a cryostat. Fluorescent microscopy was used to identify activated neurons. The expression of c-Fos was assessed by immunofluorescence. We applied anti-c-Fos antibody (1:2000; Calbiochem, Darmstadt, Germany) overnight at 4 °C and then incubated Cy3-conjugated goat anti-rabbit IgG (1:400; Fisher, Invitrogen, Carlsbad, CA, United States) for 2 h at room temperature. Pictures were taken using a fluorescence microscope (DM5500 B; Leica Microsystems Ltd., Wetzlar, Germany) at magnification × 10, and the number of c-Fos immunoreactive cells in lamina I and II of the dorsal horn at the L6-S1 segment of the spinal cord was counted for each mouse. The average number of stained nuclei in three 20 μm thick slices for each mouse was used for analysis.

Semiquantitative PCR for the detection of *TNF- α* , *IL-1 β* and *IL-10* mRNA in the spinal cord

Total RNA from L6-S1 spinal cord segments was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, United States). RNA was purified according to the manufacturer's instructions. Total RNA was treated with DNase I (Invitrogen) to remove any contaminating DNA. DNase I was stopped with DNase inactivation reagent (Invitrogen) according to the manufacturer's instructions. The quality and quantity of total RNA were determined using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Wilmington, MA, United States). The ratio of absorbance at 260 nm and 280 nm was used to assess the purity of RNA. A ratio of ≥ 2.0 was accepted for analysis.

After reverse transcription of 1.5 μ g total RNA into cDNA by using 200 units of SuperScript II Reverse Transcriptase (Invitrogen), quantitative PCR was performed using SYBR Green technology on a Bio-Rad CFX96 real time PCR system (Bio-Rad Laboratories, Marnes-la-Coquette, France). The *GAPDH* gene was chosen as the reference gene. All samples were performed in duplicate in a single 96-well reaction plate. Serially diluted cDNA samples were used as external standards. The absolute quantification of mRNA was performed by converting the sample Ct values to concentration (copies per μ L) based on standard curves. The identity and purity of the amplified products were assessed using melting curve analysis at the end of amplification. The technique was used to assay *TNF- α* , *IL-1 β* and *IL-10* mRNA in the spinal cord. The primer sequences for the targeted mouse genes are presented in [Supplementary Table 1](#).

Analysis of microglia cells

Green fluorescent protein on the fractalkine receptor-positive transgenic mice were perfused as described for c-Fos immunofluorescence, and the dorsal horn of L6-S1 spinal cord was embedded in Tissue-Tek[®] optimal cutting temperature compound, snap-frozen and cut with a cryostat. Pictures were then taken with the Leica photonic microscope used for c-Fos experiments at magnification $\times 10$, and the number of microglia cells expressing microglia green fluorescent protein in lamina I and II of L6-S1 dorsal spinal cord was counted using NIH ImageJ software (version 2.0.0-rc-43/1.51u)[20]. The average number of stained nuclei per field in three 20 μ m thick slices for each mouse was used for statistics.

Pharmacologic studies

Minocycline (2.5 mg/mL; 1.25 mg/kg; Sigma-Aldrich), a microglia blocker, CP 99994 (15 mg/mL; 7.5 mg/kg; Sigma-Aldrich), a NK1R antagonist, SB203580 (5 mg/mL; 2.5 mg/kg; Calbiochem, Merck, EMD Millipore Corp., Billerica, MA, United States), a MAPK-p38 blocker, or saline were injected in the intracerebroventricular (ICV) region using a Hamilton syringe (NeuroS[™], Gastight, 1705, 33 gauge; Dutscher, Bernolsheim, France) 1 h before injecting acetic acid (0.75%) into the bladder. Intrathecal injections of minocycline at the L6-S1 Level of the spinal cord were also performed to demonstrate that microglia activation occurred at that level.

Western blot analysis

After euthanasia, the L6-S1 segment of the mice spinal cord was removed on ice and quickly frozen in liquid nitrogen. After thawing on ice, the spinal cord samples were homogenized at 4 °C in a lysis buffer (100 μ L of buffer A $\times 2$, 2 μ L of 100 mmol/L dithiothreitol, 50 μ L of 1% NP40, 1 μ L of 1 \times P8340 protease inhibitors, 2 μ L of 1 \times P2850 phosphatase inhibitors and 200 mL of H₂O). Samples were displayed on ice for 15 min, then centrifuged at 12000 \times g for 15 min at 4 °C. The protein-containing supernatant was collected and stored at -80 °C until analysis. The proteins (25 μ g) were loaded on a 4%-20% gradient polyacrylamide gel (Bio-Rad) and transferred onto a nitro-cellulose membrane (GE Healthcare, Orsay, France). Membranes were then blocked for 1 h at room temperature with 5% (w/v) nonfat dry milk in Tris buffered saline containing 0.05% Tween[®] 20 (Sigma-Aldrich). An overnight incubation at 4 °C was then performed with primary antibodies: anti-P-p38 (1:500; Cell Signaling Technology[®], Leiden, The Netherlands; P/N 4511) or anti-NK1R (1:200; Atlas Antibodies, Bromma, Sweden; P/N HPA074573) from rabbit or anti-GAPDH (1:5000; Santa Cruz Biotechnology, Tebu-Bio, Le Perray en Yvelines, France) from goat. All antibodies were diluted in a blocking solution. After three washes, a 1-h incubation was performed with a peroxidase-conjugated IgG secondary antibody from goat anti-rabbit or from rabbit anti-goat (1:5000; Santa Cruz Biotechnology, Tebu-Bio, Le Perray en Yvelines, France). After three additional washes, immunocomplexes were revealed using the ECL detection system (GE Healthcare Life Sciences, Little Chalfont, United Kingdom). Proteins were quantified by densitometry using ImageScanner III and ImageQuant TL software (GE Healthcare Life Sciences), and standardized against the intensity of GAPDH.

Statistical analyses

The data were expressed as mean \pm standard error of the mean. Quantitative data was compared between groups using an unpaired *t*-test, with Welch's correction in case of unequal variances. Comparisons of multiple groups were performed using one-way analysis of variance (Kruskal-Wallis test) with post-hoc analysis (Dunn's multiple comparison post-test to compare all pairs of columns to each other or Dunnett's post-test to compare all pairs of columns to controls) to assess the difference among the groups, and two-way analysis of variance with post-hoc analysis (Bonferroni's correction)




Figure 1 Assessment of visceromotor response to colorectal distensions. A-C: Changes in intracolonic pressure in response to isobaric colorectal distensions (15, 30, 45 and 60 mmHg) after intravesical injections of acetic acid (0.75%) vs saline (NaCl 0.9%) in mice at 1 h (A), 1 d (B) and 7 d (C) after injections, with details of the comparison at 60 mmHg of distension on the right. $n = 8$ mice per group. ^a $P < 0.05$ and ^b $P < 0.001$. Variability in the results is represented by the standard error of the mean (area under the curve \pm standard error of the mean). AUC: Area under the curve.

was used to assess groups with repeated measures. Individual data for visceral sensitivity in mice, especially the kinetics of visceromotor responses to increasing CRD, was visually assessed for each experimental group separately; tracings of animals with aberrant or outlier responses to distensions were excluded from the analysis. A P value < 0.05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism version 9.3.1 for Windows (GraphPad Software Inc., San Diego, CA, United States, www.graphpad.com). The statistical methods used in this study were reviewed by Fabien Wuestenberghs from CHU UCL Namur.

RESULTS

Development and validation of a mouse model of chronic bladder-colon cross-sensitization

Based on our previous rat study[9], we tested the intravesical administration of a 0.75% acetic acid solution in mice. A single intravesical injection of 0.75% acetic acid under ultrasound monitoring induced an increase of the colonic nociceptive response during CRD at 30 mmHg ($P < 0.05$), 45 mmHg ($P < 0.05$) and 60 mmHg ($P < 0.001$) 1 h after injection (Figure 1). An increased colonic nociceptive response during CRD was still observed at 60 mmHg ($P < 0.05$) on 7th d in the acetic acid group compared to the control group (Figure 1), confirming that colonic hypersensitivity persists up to 7 d after the intravesical injection in our model. Further experiments were therefore designed to understand the mechanisms of the chronicization of cross-sensitization in this model. No serious adverse events occurred during the experiments.

Permeability and inflammatory parameters of bladder and colon

No differences were found at day 7 in either bladder or colon permeabilities or MPO activities between animals treated with acetic acid or saline intravesically (Figure 2).




Figure 2 Bladder and colorectal permeabilities and inflammation. A-D: Urinary bladder (A) and colorectal (B) permeabilities assessed by fluorescein isothiocyanate (FITC)-dextran, and urinary bladder (C) and colon (D) inflammatory levels assessed by myeloperoxidase (MPO) activities. They were not different between mice with intravesical injections of saline (NaCl 0.9%) or acetic acid (0.75%) at day 7. $n = 4-5$ mice per group. Results of mice treated by intravesical injections of acetic acid were normalized to those of mice treated with saline. Variability in the results is represented by the standard error of the mean.




Figure 3 Quantification of c-Fos immunoreactive cells. Quantification of c-Fos immunoreactive (IR) cells in lamina I and II of the dorsal horn per slice of the L6-S1 spinal cord on day 7 after intravesical injection of saline (NaCl 0.9%) or acetic acid 0.75%, with or without prior colorectal distensions (CRDs) at 45 mmHg for 120 min ($n = 6-7$ mice per group). ^a $P < 0.05$ and ^b $P < 0.0001$ (compared to mice treated with saline and no prior CRD); ^c $P < 0.001$ (compared to mice treated with saline and prior CRD); ^d $P < 0.01$ (compared to mice treated with acetic acid and no prior CRD). Results are expressed as the mean \pm standard error of the mean.


Neural activation in the dorsal horn of the spinal cord L6-S1

In the absence of CRD, the number of c-Fos immunoreactive cells in lamina I and II of the L6-S1 level of the dorsal horn was 6.5 ± 0.7 per slice in mice treated with saline. The CRD performed on the 7th d in these mice treated with saline increased the number of c-Fos immunoreactive cells to 12.4 ± 1.3 ($P < 0.05$). In mice treated with 0.75% acetic acid, the number of c-Fos immunoreactive cells was 12.9 ± 1.3 in the absence of CRD and increased to 23.2 ± 1.5 ($P < 0.05$ vs all other groups) after CRD (Figure 3).

Implication of central microglia from the dorsal horn of the spinal cord L6-S1 in bladder-colon cross-sensitization

The number of microglial cells has been observed in a transgenic mouse model that specifically expresses green fluorescent protein associated with the fractalkine receptor (Figure 4A and B). Seven days after injection of a 0.75% acetic acid solution into the bladder, the number of microglial cells increased compared to mice injected with saline (113.4 ± 13.0 vs 102.9 ± 11.2 per field, respectively, $P < 0.05$) (Figure 4C).

We administered minocycline, a microglial inhibitor, at the central level 1 h before the intravesical injection of acetic acid or saline to demonstrate the involvement of microglia cells. Both intrathecal and



DOI: 10.3748/wjg.v28.i48.6935 Copyright ©The Author(s) 2022.

Figure 4 Number of microglia cells in the spinal cord. A and B: Microglial cells in the dorsal horn of the L6-S1 level of the spinal cord were stained green [green fluorescent protein on the fractalkine receptor-positive (CX3CR1^{GFP+}) mice], while nuclei appear in blue (DAPI) at day 7 after intravesical injections of saline (NaCl 0.9%) (A) or acetic acid 0.75% (B); C: The number of microglial cells per field was compared between the two groups using a Mann-Whitney bilateral test ($n = 5$ per group, average of 23 slices analyzed per mouse). ^a $P < 0.05$. Results are expressed as the mean \pm standard error of the mean.

ICV injections of minocycline prevented the development of cross-sensitization induced by intravesical administration of acetic acid (Figure 5A and B). ICV injections were favored for the following experiments because they are less traumatic and cause less stress to the animals.

Involvement of central NK1R in bladder-colon cross-sensitization

The ICV injection of CP 99994, a NK1R antagonist, 1 h before the intravesical injection of acetic acid, prevented the development of bladder-colon cross-sensitization compared to mice treated intracerebroventricularly by saline (Figure 6A). The intravesical administration of acetic acid increased the phosphorylation of MAPK-p38, a microglial protein involved in chronic pain generation[21], compared to mice injected intravesically with saline, but the ICV injection of CP 99994 prevented this phosphorylation, suggesting that microglial activation depends on the activation of NK1R (Figure 6B).

The ICV injection of SB203580, a MAPK-p38 inhibitor, 1 h before the intravesical injection of acetic acid prevented the occurrence of bladder-colon cross-sensitization (Figure 7A). The intravesical administration of acetic acid induced an increase in NK1R expression in the posterior horn of the L6-S1 level of the spinal cord compared to the administration of saline (Figure 7B). Acetic acid-induced spinal overexpression of NK1R was blocked by prior ICV administration of SB203580 (Figure 7B), suggesting that the MAPK-p38 pathway is involved in the development of bladder-colon cross-sensitization.

Assessment of the expression of spinal pro- and anti-inflammatory transcripts

Expression levels of *IL-1 β* , *TNF- α* and *IL-10* mRNA did not differ between control and acetic acid groups ($P = 0.22$, 0.47 and 0.19 , respectively) (Figure 8).

DISCUSSION

A mouse model of bladder to colon cross-sensitization with persistent visceral hypersensitivity in the colorectum has not been developed until now to our knowledge. Our study showed that pelvic visceral cross-sensitization involves central sensitization with microglia modulation following a peripheral




Figure 5 Effect of minocycline injection at the central level on visceral sensitivity. A and B: Changes in intracolonic pressure in response to isobaric colorectal distensions (15, 30, 45 and 60 mmHg) intrathecal (IT) injections of saline (NaCl 0.9%) (A) or minocycline (1.25 mg/kg) prior to intravesical (IV) injections of acetic acid 0.75% and after intracerebroventricular (ICV) injections of saline or minocycline (1.25 mg/kg) (B) prior to IV injections of saline or acetic acid 0.75% in mice at day 7, both with details of the comparison at 60 mmHg of distension on the right. $n = 6-8$ mice per group. ^a $P < 0.05$ and ^b $P < 0.001$ (compared to the minocycline IT + acetic acid IV group); ^c $P < 0.0001$ (compared to the saline ICV + saline IV group); ^d $P < 0.05$ (compared to the minocycline ICV + acetic acid IV group). Variability in the results is represented by the standard error of the mean (area under the curve \pm standard error of the mean). AUC: Area under the curve.

inflammatory event and is mediated by the NK1 and MAPK-p38 pathways.

The pathophysiology of colon-bladder cross-sensitization is complex and probably involves both peripheral and central mechanisms including: the sensitization of sensory nerve terminals in both organs; cross-sensitization of adjacent sensory primary afferent neurons within dorsal root ganglia (involving satellite glia cells and macrophages); axon reflexes *via* primary sensory afferent neurons with a dichotomizing axon explaining neurogenic inflammation if there is a convergence of sensory information from distinct organs to a single neuron and antidromic release of inflammatory mediators in the unaffected organ (pre-spinal convergence); the sensitization of second order spinal neurons in which there is a convergence of inputs from both colon and bladder, involving spinal interneurons (convergence-projection theory or dorsal root reflex); and supraspinal mechanisms (modified central processing of visceral stimuli in the amygdala, *etc.*)[10]. Our work adds to the current understanding that central sensitization in the spinal cord involves microglia modulation and is mediated by the NK1 and MAPK-p38 pathways.

It is already known that an increase in proinflammatory factors within the bladder tissue can sensitize the colon[22-24]. Several mechanisms have been proposed to explain this inter-organ sensitization. These mechanisms include the increased mechanical sensitivity of visceral muscle afferents, a higher proportion of chemosensitive visceral afferents[23], brainstem neurons integrating somatovisceral messages after bladder irritation[25], and central sensitization resulting from stressful life events[26].

In our study, we used a mouse model of colonic visceral hypersensitivity induced by cross-organ sensitization to demonstrate that microglia play a central role in the development of this hypersensitivity. Indeed, we showed that the ICV injection of minocycline, which is known to be an inhibitor of microglial cells, blocks the cross-sensitization process. It has already been shown that minocycline also induces a decrease in neuronal excitability by preventing phosphorylation of the ERK protein and MAPK, which are expressed in the spinal cord[27]. The analgesic effect of minocycline is mediated by its action in both microglial activation and neuronal activation. Microglial cells have already been shown to be recruited during colonic sensitization induced by chronic stress in rats[12], but our study is the first to identify the crucial role of microglia in bladder to colon cross-sensitization and in a mouse model.

We showed that the role of microglia in the development of cross-sensitization from the bladder to the colon is mediated by the tachykinergic pathway, particularly involving NK1R. This receptor activates, directly or indirectly, the MAPK-p38 protein *via* its phosphorylation. Several studies have




Figure 6 Effect of CP 99994 injection at the central level on visceral sensitivity and the expression of phosphorylated MAPK-p38. **A:** Changes in intracolonic pressure in response to isobaric colorectal distensions (15, 30, 45 and 60 mmHg) after intracerebroventricular (ICV) injections of saline (NaCl 0.9%) or CP 99994 (7.5 mg/kg) prior to intravesical (IV) injection of saline or acetic acid 0.75% in mice at day 7, with details of the comparison at 60 mmHg of distension on the right. $n = 8$ mice per group; **B:** Expression of phosphorylated MAPK-p38 (P-p38) at the L6-S1 level of the spinal cord, with quantitative analysis (ratio to the reference protein GAPDH) on the right. Samples were run on separate gels and compiled for the figure. $n = 5-8$ mice per group. ^a $P < 0.05$, ^b $P < 0.01$ and ^c $P < 0.001$ (compared to the saline ICV + saline IV group); ^d $P < 0.05$ and ^e $P < 0.001$ (compared to the CP 99994 ICV + acetic acid IV group). Variability in the results is represented by the standard error of the mean (area under the curve \pm standard error of the mean). AUC: Area under the curve.

confirmed that MAPK-p38 is expressed only by microglial cells[21,28,29]. Its involvement in the course of chronic stress-induced colonic sensitization has already been demonstrated in rats[12]. Another study suggested that the activation of microglial MAPK-p38 protein at the ventromedial nucleus of the spinal cord (rostral ventromedial medulla) was responsible for uterocolonic cross-sensitization in an acute model[30]. In our work, we found that visceral hypersensitivity induced by chronic stress was associated with the phosphorylation of MAPK-p38 at the microglial cell level in mice and that this effect was inhibited by the ICV injection of a MAPK-p38 inhibitor (SB203580).

Bradesi *et al*[12] also showed that the fractalkine receptor potentiates the development of visceral hypersensitivity *via* a chemokine function on NK1R. The activation of MAPK-p38 is known to be associated with the increased synthesis and secretion of several neurotransmitters of inflammation, such as COX2, IL-1 β , inducible nitric oxide synthase, PLA2 and PGE2[31]. The mediators of inflammation involved in our model are probably different from those involved in the trinitrobenzenesulfonic acid-induced colitis models, in which expression of IL-1 β is upregulated in the spinal cord[32] since we did not demonstrate any changes at the *TNF- α* , *IL-1 β* and *IL-10* mRNA level.

We therefore propose a mechanistic view of the molecular and cellular mechanisms underlying the development of colonic hypersensitivity by bladder-to-colon cross-sensitization in which the inflammatory reaction following irritation of the urothelium induces the activation of extrinsic primary afferent neurons, some of them co-innervating the bladder and the colon and giving rise to axon reflexes, while others innervating the colon are activated by paracrine interactions. Convergent neurons in the dorsal root ganglia and the spinal cord, and those innervating the colon secondarily sensitize the colon. Some activated extrinsic primary afferent neurons relaying to other neurons in the dorsal horn of the spinal cord specifically secrete substance P, a member of the tachykinin family, which binds to NK1R activating the MAPK-p38 by phosphorylation. This in turn could either directly or indirectly induce the synthesis of mediators involved in neuroplasticity and neuroinflammation in the spinal cord.

A mini-invasive approach that specifically targets the bladder without inducing structural lesions in neighboring areas (especially the colon and peritoneum) is a prerequisite for cross-sensitization. Indeed, abdominal surgery is known to induce stress, involving a hormonal stress response at the peripheral and central levels, and implicating the corticotropin-releasing factor pathways[33]. It can induce visceral sensitization in the absence of signs of overt inflammation in mice[16]. Similarly, we decided to use measurements of the intracolonic pressure as a surrogate marker of visceromotor responses induced by CRD to assess visceral sensitivity in our study. This technique was an alternative to the measurement of




Figure 7 Effect of SB203580 injection at the central level on visceral sensitivity and the expression of NK1 receptors. A: Changes in intracolonic pressure in response to isobaric colorectal distensions (15, 30, 45 and 60 mmHg) after intracerebroventricular (ICV) injections of saline (NaCl 0.9%) or SB203580 (2.5 mg/kg) prior to intravesical (IV) injection of saline or acetic acid 0.75% in mice at day 7, with details of the comparison at 60 mmHg of distension on the right. $n = 8$ mice per group; B: Expression of NK1R at the L6-S1 level of the spinal cord, with quantitative analysis (ratio to the reference protein GAPDH) on the right. Samples were run on separate gels and compiled for the figure. $n = 5-8$ mice per group. ^a $P < 0.05$ and ^b $P < 0.001$ (compared to the saline ICV + saline IV group); ^c $P < 0.05$ and ^d $P < 0.01$ (compared to the SB203580 ICV + acetic acid IV group). Variability in the results is represented by the standard error of the mean (area under the curve \pm standard error of the mean). AUC: Area under the curve.




Figure 8 Expression of inflammatory cytokines in the spinal cord. A-C: Expression levels of *TNF-α* (A), *IL-1β* (B) and *IL-10* (C) mRNA in the L6-S1 level of the spinal cord on day 7 were not different between mice with intravesical injections of acetic acid 0.75% or saline (NaCl 0.9%) on day 7. $n = 7$ per group. Results were expressed as the mean \pm standard error of the mean. AU: Arbitrary unit.

the electromyographic activity of the abdominal muscles[34] and had the advantage of being minimally invasive.

When we planned our study, the available animal models for the study of bladder-bowel interactions included acute[11] and chronic[35,36] colon irritation with 2,4,6-trinitrobenzenesulfonic acid in mice[36] and in rats[11] and acute bladder irritation by cyclophosphamide, an antitumoral drug known to induce hemorrhagic cystitis in mice[35] and by infusing protamine sulphate and potassium chloride in rats[11]. In those studies, colonic sensitivity was assessed on day 5 after bladder irritation in mice and on the day of the irritation in rats.

The main limitation of our model is that the chronicity of the cross-organ sensitization was considered at day 7 following bladder irritation in mice. This period may seem short in view of clinical situations that evolve over several years. However, no other inflammatory model of cross-sensitization from the bladder to the colon published in the literature exceeds 48 h[35]. Furthermore, stress-induced chronic colonic sensitization models with 11 d of homotypic stress[12] were shown to be sufficient to induce changes in colonic tenderness and spinal microglia modulation. Our 7-d period in mice therefore seems to be long enough to attest to the chronicity of the process. Further studies with a longer longitudinal assessment of visceral sensitivity are necessary to confirm our results. Our results can only be extrapolated to males because sex-dependent differences in the responses to the sensitization process[37, 38] and microglia[39] have been reported. Since pelvic neuroanatomy is similar in other rodents and in humans, we could expect similar results in those species, which could explain in part the common overlap between BPS and IBS in the clinic.

CONCLUSION

In conclusion, we have developed the first model of cross-organ chronic visceral sensitization between bladder and colon in mice. Pelvic cross-sensitization involves central sensitization with microglia modulation and is mediated by the NK1 receptor pathway and MAPK-p38 activation.

ARTICLE HIGHLIGHTS

Research background

Limited mechanistic data is available in the context of overlap between bladder pain syndrome and irritable bowel syndrome. Based on the fact that pelvic organs share common sensory pathways, a few studies have offered evidence that cross-sensitization between the bladder and the colon may explain sensitization of both organs. This may involve primary extrinsic afferents or central sensitization, both at the spinal and supraspinal levels.

Research motivation

The precise pathophysiology involved in cross-sensitization of the bladder and the colon remains poorly understood.

Research objectives

The objectives of this study were to develop a model of chronic bladder-colon cross-sensitization and to investigate the mechanisms involved.

Research methods

Chronic cross-organ visceral sensitization was obtained in C57BL/6 mice using ultrasound-guided intravesical injections of acetic acid under brief isoflurane anesthesia. Colorectal sensitivity was assessed in conscious mice by measuring intracolonic pressure during isobaric colorectal distension. Three different inhibitors/antagonists were assessed to gain a better understanding of which pathway could be involved in the cross-sensitization process.

Research results

Visceral hypersensitivity to colorectal distension was observed after the intravesical injection of acetic acid. This effect started 1 h post-injection and lasted up to 7 d post-injection. Colorectal sensitization was prevented by intrathecal or intracerebroventricular injections of minocycline, a microglia inhibitor, by intracerebroventricular injection of CP-99994 dihydrochloride, a NK1 antagonist, and by intracerebroventricular injection of SB203580, a MAPK-p38 inhibitor.

Research conclusions

We described a new model of cross-organ visceral sensitization between the bladder and the colon in mice lasting up to 7 d. Intravesical injections of acetic acid induced colorectal hypersensitivity to

distension, mediated by neuroglial interactions, MAPK-p38 phosphorylation and the NK1 receptor.

Research perspectives

A bladder-colon chronic cross-sensitization mouse model using intravesical injections of acetic acid can be used as a preclinical model of overlap between bladder pain syndrome and irritable bowel syndrome.

ACKNOWLEDGEMENTS

The authors thank Professor Paul Mulder and Professor Vincent Richard (Inserm Unit 1096, Rouen, France) for sharing their ultrasound machine.

FOOTNOTES

Author contributions: Gourcerol G and Leroi AM designed the research study; Atmani K, Meleine Mathieu, Baron M, Bouleté I, Guérin C, Vaudry D, do Rego JC and Bahlouli W performed the research; Atmani K, Wuestenberg F, Meleine M and Gourcerol G analyzed the data; Atmani K, Wuestenberg F and Gourcerol G drafted the manuscript; Atmani K, Wuestenberg F, Baron M, Bouleté I, Guérin C, Bahlouli W, Vaudry D, do Rego JC, Cornu JN, Leroi AM, Coëffier M, Meleine M and Gourcerol G critically reviewed the manuscript for important intellectual content; All authors approved the final version of the article, including the authorship list; Gourcerol G accepts official responsibility for the overall integrity of the manuscript.

Institutional animal care and use committee statement: All animal experiments conformed to the internationally accepted principles for the care and use of laboratory animals, and the protocol was approved by the local Ethics Committee for Animal Experiments (CENOMEXA No: N/02-01-13/02/01-16).

Conflict-of-interest statement: None of the authors have any conflicts of interest.

Data sharing statement: No additional data is available.

ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: France

ORCID number: Karim Atmani 0000-0003-3584-0694; Fabien Wuestenberg 0000-0001-6100-6017; Maximilien Baron 0000-0001-8496-9203; Illona Bouleté 0000-0003-1697-5999; Charlene Guérin 0000-0003-0585-8754; Wafa Bahlouli 0000-0002-0049-240X; David Vaudry 0000-0003-3567-7452; Jean Claude do Rego 0000-0001-5706-3780; Jean-Nicolas Cornu 0000-0002-6735-1601; Anne-Marie Leroi 0000-0002-6266-4203; Moïse Coëffier 0000-0002-7469-2682; Mathieu Meleine 0000-0002-0925-087X; Guillaume Gourcerol 0000-0001-8220-9155.

S-Editor: Zhang H

L-Editor: Filipodia

P-Editor: Zhang H

REFERENCES

- 1 **Alagiri M**, Chottiner S, Ratner V, Slade D, Hanno PM. Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. *Urology* 1997; **49**: 52-57 [PMID: 9146002 DOI: 10.1016/s0090-4295(99)80332-x]
- 2 **Nickel JC**, Tripp DA, Pontari M, Moldwin R, Mayer R, Carr LK, Doggweiler R, Yang CC, Mishra N, Nordling J. Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. *J Urol* 2010; **184**: 1358-1363 [PMID: 20719340 DOI: 10.1016/j.juro.2010.06.005]
- 3 **Palsson OS**, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. *Gastroenterology* 2020; **158**: 1262-1273.e3 [PMID: 31917991 DOI: 10.1053/j.gastro.2019.12.021]
- 4 **Suskind AM**, Berry SH, Ewing BA, Elliott MN, Suttorp MJ, Clemens JQ. The prevalence and overlap of interstitial

- cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. *J Urol* 2013; **189**: 141-145 [PMID: 23164386 DOI: 10.1016/j.juro.2012.08.088]
- 5 Mathieu N. [Somatic comorbidities in irritable bowel syndrome: fibromyalgia, chronic fatigue syndrome, and interstitial cystitis]. *Gastroenterol Clin Biol* 2009; **33** Suppl 1: S17-S25 [PMID: 19303534 DOI: 10.1016/S0399-8320(09)71521-0]
 - 6 Naliboff BD, Munakata J, Fullerton S, Gracely RH, Kodner A, Harraf F, Mayer EA. Evidence for two distinct perceptual alterations in irritable bowel syndrome. *Gut* 1997; **41**: 505-512 [PMID: 9391250 DOI: 10.1136/gut.41.4.505]
 - 7 Lai HH, Vetter J, Jain S, Gereau RW 4th, Andriole GL. The overlap and distinction of self-reported symptoms between interstitial cystitis/bladder pain syndrome and overactive bladder: a questionnaire based analysis. *J Urol* 2014; **192**: 1679-1685 [PMID: 24907443 DOI: 10.1016/j.juro.2014.05.102]
 - 8 Barbara G, Cremon C, De Giorgio R, Dothel G, Zecchi L, Bellacosa L, Carini G, Stanghellini V, Corinaldesi R. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. *Curr Gastroenterol Rep* 2011; **13**: 308-315 [PMID: 21537962 DOI: 10.1007/s11894-011-0195-7]
 - 9 Langlois LD, Le Long E, Meleine M, Antor M, Atmani K, Dechelotte P, Leroi AM, Gourcerol G. Acute sacral nerve stimulation reduces visceral mechanosensitivity in a cross-organ sensitization model. *Neurogastroenterol Motil* 2017; **29** [PMID: 27997083 DOI: 10.1111/nmo.12987]
 - 10 Brumovsky PR, Gebhart GF. Visceral organ cross-sensitization - an integrated perspective. *Auton Neurosci* 2010; **153**: 106-115 [PMID: 19679518 DOI: 10.1016/j.autneu.2009.07.006]
 - 11 Pezzone MA, Liang R, Fraser MO. A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders. *Gastroenterology* 2005; **128**: 1953-1964 [PMID: 15940629 DOI: 10.1053/j.gastro.2005.03.008]
 - 12 Bradesi S, Svensson CI, Steinauer J, Pothoulakis C, Yaksh TL, Mayer EA. Role of spinal microglia in visceral hyperalgesia and NK1R up-regulation in a rat model of chronic stress. *Gastroenterology* 2009; **136**: 1339-1348, e1 [PMID: 19249394 DOI: 10.1053/j.gastro.2008.12.044]
 - 13 Qiao LY, Tiwari N. Spinal neuron-glia-immune interaction in cross-organ sensitization. *Am J Physiol Gastrointest Liver Physiol* 2020; **319**: G748-G760 [PMID: 33084399 DOI: 10.1152/ajpgi.00323.2020]
 - 14 Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. *Pain* 1983; **16**: 109-110 [PMID: 6877845 DOI: 10.1016/0304-3959(83)90201-4]
 - 15 Brifault C, Gras M, Liot D, May V, Vaudry D, Wurtz O. Delayed pituitary adenylate cyclase-activating polypeptide delivery after brain stroke improves functional recovery by inducing m² microglia/macrophage polarization. *Stroke* 2015; **46**: 520-528 [PMID: 25550371 DOI: 10.1161/STROKEAHA.114.006864]
 - 16 Larauche M, Gourcerol G, Million M, Adelson DW, Taché Y. Repeated psychological stress-induced alterations of visceral sensitivity and colonic motor functions in mice: influence of surgery and postoperative single housing on visceromotor responses. *Stress* 2010; **13**: 343-354 [PMID: 20536336 DOI: 10.3109/10253891003664166]
 - 17 Beutheu S, Ouelaa W, Guérin C, Belmonte L, Aziz M, Tennoune N, Bôle-Feysot C, Galas L, Déchelotte P, Coëffier M. Glutamine supplementation, but not combined glutamine and arginine supplementation, improves gut barrier function during chemotherapy-induced intestinal mucositis in rats. *Clin Nutr* 2014; **33**: 694-701 [PMID: 24095638 DOI: 10.1016/j.clnu.2013.09.003]
 - 18 Meleine M, Boudieu L, Gelot A, Muller E, Lashermes A, Matricon J, Silberberg C, Theodorou V, Eschalièr A, Ardid D, Carvalho FA. Comparative effects of $\alpha 2\delta$ -1 Ligands in mouse models of colonic hypersensitivity. *World J Gastroenterol* 2016; **22**: 7111-7123 [PMID: 27610021 DOI: 10.3748/wjg.v22.i31.7111]
 - 19 Maaser C, Kannengiesser K, Specht C, Lügering A, Brzoska T, Luger TA, Domschke W, Kucharzik T. Crucial role of the melanocortin receptor MC1R in experimental colitis. *Gut* 2006; **55**: 1415-1422 [PMID: 16543288 DOI: 10.1136/gut.2005.083634]
 - 20 Rasband WS. Image J. U.S. National Institutes of Health, Bethesda, Maryland, USA. Available from: <https://imagej.nih.gov/ij/>
 - 21 Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. *J Neurosci* 2003; **23**: 4017-4022 [PMID: 12764087 DOI: 10.1523/JNEUROSCI.23-10-04017.2003]
 - 22 Malykhina AP. Neural mechanisms of pelvic organ cross-sensitization. *Neuroscience* 2007; **149**: 660-672 [PMID: 17920206 DOI: 10.1016/j.neuroscience.2007.07.053]
 - 23 Brumovsky PR, Feng B, Xu L, McCarthy CJ, Gebhart GF. Cystitis increases colorectal afferent sensitivity in the mouse. *Am J Physiol Gastrointest Liver Physiol* 2009; **297**: G1250-G1258 [PMID: 19779012 DOI: 10.1152/ajpgi.00329.2009]
 - 24 Furuta A, Suzuki Y, Naruoka T, Asano K, Egawa S, Yoshimura N. Cross-sensitization mechanisms between colon and bladder via transient receptor potential A1 stimulation in rats. *Int Urogynecol J* 2014; **25**: 1575-1581 [PMID: 24828604 DOI: 10.1007/s00192-014-2405-y]
 - 25 Kaddumi EG, Hubscher CH. Changes in rat brainstem responsiveness to somatovisceral inputs following acute bladder irritation. *Exp Neurol* 2007; **203**: 349-357 [PMID: 17010973 DOI: 10.1016/j.expneurol.2006.08.011]
 - 26 Mayer EA. Gut feelings: the emerging biology of gut-brain communication. *Nat Rev Neurosci* 2011; **12**: 453-466 [PMID: 21750565 DOI: 10.1038/nrn3071]
 - 27 Cho IH, Lee MJ, Jang M, Gwak NG, Lee KY, Jung HS. Minocycline markedly reduces acute visceral nociception via inhibiting neuronal ERK phosphorylation. *Mol Pain* 2012; **8**: 13 [PMID: 22364340 DOI: 10.1186/1744-8069-8-13]
 - 28 Ji RR, Suter MR. p38 MAPK, microglial signaling, and neuropathic pain. *Mol Pain* 2007; **3**: 33 [PMID: 17974036 DOI: 10.1186/1744-8069-3-33]
 - 29 Ji RR, Berta T, Nedergaard M. Glia and pain: is chronic pain a gliopathy? *Pain* 2013; **154** Suppl 1: S10-S28 [PMID: 23792284 DOI: 10.1016/j.pain.2013.06.022]
 - 30 Chen Z, Xie F, Bao M, Li X, Chao Y, Lin C, Guo R, Zhang C, Wu A, Yue Y, Guan Y, Wang Y. Activation of p38 MAPK in the rostral ventromedial medulla by visceral noxious inputs transmitted via the dorsal columns may contribute to pelvic organ cross-sensitization in rats with endometriosis. *Neuroscience* 2015; **291**: 272-278 [PMID: 25701711 DOI: 10.1016/j.neuroscience.2015.02.021]

- 31 **Svensson CI**, Hua XY, Protter AA, Powell HC, Yaksh TL. Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE(2) release and thermal hyperalgesia. *Neuroreport* 2003; **14**: 1153-1157 [PMID: 12821799 DOI: 10.1097/00001756-200306110-00010]
- 32 **Majima T**, Funahashi Y, Kawamorita N, Takai S, Matsukawa Y, Yamamoto T, Yoshimura N, Gotoh M. Role of microglia in the spinal cord in colon-to-bladder neural crosstalk in a rat model of colitis. *Neurorol Urodyn* 2018; **37**: 1320-1328 [PMID: 29350427 DOI: 10.1002/nau.23484]
- 33 **Taché Y**, Bonaz B. Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. *J Clin Invest* 2007; **117**: 33-40 [PMID: 17200704 DOI: 10.1172/JCI30085]
- 34 **Larauche M**, Gourcerol G, Wang L, Pambukchian K, Brunnhuber S, Adelson DW, Rivier J, Million M, Taché Y. Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways. *Am J Physiol Gastrointest Liver Physiol* 2009; **297**: G215-G227 [PMID: 19407218 DOI: 10.1152/ajpgi.00072.2009]
- 35 **Bielefeldt K**, Lamb K, Gebhart GF. Convergence of sensory pathways in the development of somatic and visceral hypersensitivity. *Am J Physiol Gastrointest Liver Physiol* 2006; **291**: G658-G665 [PMID: 16500917 DOI: 10.1152/ajpgi.00585.2005]
- 36 **Lamb K**, Zhong F, Gebhart GF, Bielefeldt K. Experimental colitis in mice and sensitization of converging visceral and somatic afferent pathways. *Am J Physiol Gastrointest Liver Physiol* 2006; **290**: G451-G457 [PMID: 16195421 DOI: 10.1152/ajpgi.00353.2005]
- 37 **Ji Y**, Tang B, Cao DY, Wang G, Traub RJ. Sex differences in spinal processing of transient and inflammatory colorectal stimuli in the rat. *Pain* 2012; **153**: 1965-1973 [PMID: 22819535 DOI: 10.1016/j.pain.2012.06.019]
- 38 **Yoshiyama M**, Kobayashi H, Araki I, Du S, Zakoji H, Takeda M. Sex-related differences in activity of lower urinary tract in response to intravesical acid irritation in decerebrate unanesthetized mice. *Am J Physiol Regul Integr Comp Physiol* 2008; **295**: R954-R960 [PMID: 18650315 DOI: 10.1152/ajpregu.90406.2008]
- 39 **Guneykaya D**, Ivanov A, Hernandez DP, Haage V, Wojtas B, Meyer N, Maricos M, Jordan P, Buonfiglioli A, Gielniewski B, Ochocka N, Cömert C, Friedrich C, Artiles LS, Kaminska B, Mertins P, Beule D, Kettenmann H, Wolf SA. Transcriptional and Translational Differences of Microglia from Male and Female Brains. *Cell Rep* 2018; **24**: 2773-2783.e6 [PMID: 30184509 DOI: 10.1016/j.celrep.2018.08.001]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

